trending Market Intelligence /marketintelligence/en/news-insights/trending/BMHuzk4QEs64GVxydp7xDw2 content esgSubNav
In This List

Exelixis advanced liver cancer drug succeeds in phase 3 trial

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Exelixis advanced liver cancer drug succeeds in phase 3 trial

Exelixis Inc. said the phase 3 trial of Cabometyx met its main goal of overall survival in patients with advanced hepatocellular carcinoma, a form of liver cancer.

The CELESTIAL study, conducted in 760 patients, showed the drug is better than placebo in improving overall survival, or OS, a measure of how long a patient lives after diagnosis or start of treatment.

The study recorded a 32% increase in the median OS of patients treated with the drug versus the assumed median OS of 8.2 months for placebo.

The study's independent monitoring committee previously recommended stopping the trial for efficacy. However, the company said it will discuss the trial results with regulatory authorities and determine next steps.

The company is also planning a supplemental new drug application for Cabometyx, or cabozantinib, with the U.S. Food and Drug Administration in the first quarter of 2018.

Cabometyx is already approved in the U.S. for advanced liver cancer patients who have received prior anti-angiogenic therapy.